For the growing population of patients with the co-morbid conditions ofhypertension, diabetes, and obesity, GLP-1 RAs represent an opportunity tosimultaneously treat multiple risk factors with one agent. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.